Hospital
Mayo Clinic Health System-Southwest Minnesota Region
Mayo Clinic Health System-Southwest Minnesota Region was paid $28.51M by Medicaid between Jan 2018 and Nov 2024, across 175 billing codes. Its largest line is 99285, emergency room visit (most serious) — 38% of everything it billed.
33Billing provider infoMAYO CLINIC HEALTH SYSTEM-SOUTHWEST MINNESOTA REGION
MANKATO, MN 56001
MANKATO, MN 56001
33aNPI1154302487assigned 11/14/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$28.51M
24GClaims318,501
24DCodes billed175
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#8 of 36
Median peer was paid$11.46M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MEKALA, PRAVEEN controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,633 | $1.02M | |
| 2019 | 24,203 | $2.68M | |
| 2020 | 44,814 | $4.07M | |
| 2021 | 90,164 | $6.21M | |
| 2022 | 64,282 | $5.70M | |
| 2023 | 43,252 | $4.88M | |
| 2024incomplete | 29,153 | $3.95M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 38% | 29,913 | 25,395 | $10.80M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 19,989 | 17,193 | $4.74M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 11% | 43,613 | 41,128 | $3.14M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 16,933 | 15,731 | $2.99M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 9.1% | 30,556 | 28,407 | $2.59M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.9% | 6,094 | 5,703 | $839K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.3% | 30,102 | 28,291 | $652K |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.6% | 664 | 631 | $446K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 244 | 218 | $197K |
| 36415 | Collection of venous blood by venipuncture | <1% | 35,500 | 32,249 | $192K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,447 | 1,414 | $183K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,726 | 6,163 | $147K |
163 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,785 | $145K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,105 | $139K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 30,139 | $105K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,212 | $84K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 1,279 | $81K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 32 | $81K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,241 | $67K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,115 | $67K |
| 80053 | Comprehensive metabolic panel | <1% | 10,832 | $64K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 444 | $58K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,223 | $54K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,151 | $42K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 61 | $37K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 337 | $36K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 289 | $36K |
| 99223 | Prolong inpt eval add15 m | <1% | 282 | $35K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,168 | $28K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 533 | $24K |
| 87631 | <1% | 317 | $23K | |
| 93296 | <1% | 738 | $23K | |
| 70310 | <1% | 400 | $21K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 254 | $20K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 263 | $18K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 263 | $17K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,171 | $17K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 222 | $14K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 51 | $14K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 44 | $12K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 170 | $12K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 95 | $12K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 40 | $11K |
| 94060 | <1% | 90 | $9K | |
| 80061 | Lipid panel | <1% | 792 | $8K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 404 | $8K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 122 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 136 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 189 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 189 | $7K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 140 | $6K |
| 81001 | <1% | 2,808 | $6K | |
| 84484 | <1% | 600 | $6K | |
| 94010 | <1% | 107 | $6K | |
| 31575 | <1% | 39 | $6K | |
| 99220 | <1% | 47 | $5K | |
| 85610 | <1% | 1,304 | $5K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 90 | $5K |
| 87070 | <1% | 423 | $4K | |
| 88142 | <1% | 233 | $4K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 208 | $4K |
| 80306 | <1% | 104 | $4K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 16 | $3K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 15 | $3K |
| 76801 | <1% | 28 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 242 | $3K |
| 83690 | <1% | 540 | $2K | |
| 88307 | <1% | 24 | $2K | |
| 73630 | <1% | 136 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 49 | $2K |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 43 | $2K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $2K |
| 73610 | <1% | 57 | $2K | |
| 00811 | <1% | 14 | $2K | |
| 99221 | <1% | 30 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,460 | $2K |
| 00731 | <1% | 14 | $1K | |
| 99217 | <1% | 30 | $1K | |
| 99219 | <1% | 17 | $1K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 32 | $1K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 25 | $1K |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 39 | $1K |
| 94726 | <1% | 90 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 44 | $1K |
| 11721 | <1% | 44 | $1K | |
| 85027 | <1% | 300 | $1K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 13 | $1K |
| 83605 | <1% | 202 | $1K | |
| 73130 | <1% | 36 | $1K | |
| 81003 | <1% | 374 | $1K | |
| 95249 | <1% | 30 | $1K | |
| 86780 | <1% | 77 | $1K | |
| 86769 | <1% | 27 | $998.32 | |
| 81025 | <1% | 226 | $965.72 | |
| 84439 | <1% | 75 | $960.71 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 12 | $942.75 |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 14 | $661.79 |
| 93970 | <1% | 29 | $659.38 | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 14 | $651.31 |
| 82077 | <1% | 33 | $636.48 | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 24 | $619.92 |
| 86850 | <1% | 66 | $605.96 | |
| 93971 | <1% | 43 | $553.38 | |
| 86140 | <1% | 162 | $512.65 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 30 | $499.47 |
| 80179 | <1% | 17 | $488.40 | |
| 80143 | <1% | 17 | $488.40 | |
| 74018 | <1% | 93 | $487.09 | |
| 99152 | <1% | 62 | $467.84 | |
| 99406 | <1% | 26 | $460.95 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,488 | $453.76 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 14 | $449.18 |
| 0764T | <1% | 14 | $449.10 | |
| 0002A | <1% | 33 | $431.66 | |
| 95886 | <1% | 212 | $402.00 | |
| 82728 | <1% | 26 | $390.01 | |
| 88141 | <1% | 13 | $356.07 | |
| 73564 | <1% | 50 | $321.25 | |
| 94729 | <1% | 96 | $313.92 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13 | $270.90 |
| 88300 | <1% | 13 | $270.72 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,031 | $253.12 |
| 87340 | <1% | 26 | $252.29 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 14 | $247.56 |
| 86787 | <1% | 14 | $246.72 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $241.10 |
| 73030 | <1% | 48 | $239.82 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 16 | $219.22 |
| 82248 | <1% | 126 | $208.91 | |
| 88304 | <1% | 15 | $198.78 | |
| 82607 | <1% | 12 | $186.87 | |
| 87077 | <1% | 14 | $185.14 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,419 | $181.73 |
| 86762 | <1% | 14 | $177.87 | |
| 0001A | <1% | 21 | $177.10 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 502 | $177.04 |
| 87660 | <1% | 12 | $160.60 | |
| 87510 | <1% | 12 | $154.24 | |
| 87480 | <1% | 12 | $152.64 | |
| 82043 | <1% | 25 | $134.35 | |
| 87186 | <1% | 14 | $126.58 | |
| 86900 | <1% | 39 | $118.89 | |
| 86901 | <1% | 39 | $118.89 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,384 | $105.85 |
| 84450 | <1% | 40 | $97.44 | |
| 82570 | <1% | 14 | $97.15 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,265 | $82.28 |
| 92567 | <1% | 13 | $81.70 | |
| 85652 | <1% | 117 | $73.96 | |
| 73110 | <1% | 16 | $72.77 | |
| 82565 | <1% | 31 | $62.00 | |
| A9270 | Non-covered item or service | <1% | 55 | $58.75 |
| 84460 | <1% | 25 | $57.87 | |
| 83735 | <1% | 96 | $44.88 | |
| 86200 | <1% | 12 | $44.07 | |
| 86039 | <1% | 42 | $12.33 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 16 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 78 | $0.00 |
| 91300 | 0% | 54 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 42 | $0.00 |
| 92504 | 0% | 13 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 13 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 51 | $0.00 |
| 84702 | 0% | 14 | $0.00 | |
| 90691 | 0% | 16 | $0.00 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 64 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 13 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 211 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 56 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 178 | $0.00 |
| 85018 | 0% | 12 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 28 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 24 | $0.00 |
| J3490 | Unclassified drugs | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMEKALA, PRAVEEN (CFO)
| Provider | Location | Paid |
|---|---|---|
| Mayo Clinic Health System-Southeast Minnesota Region | Albert Lea, MN | $37.49M |
| Mayo Clinic Health System-Southeast Minnesota Region | Albert Lea, MN | $21.76M |
| Mayo Clinic Health System-Southeast Minnesota Region | Owatonna, MN | $13.72M |
| Mayo Clinic Health System-Southeast Minnesota Region | Albert Lea, MN | $12.58M |
| Mayo Clinic Health System-Fairmont | Fairmont, MN | $9.04M |
| Mayo Clinic Health System-Southeast Minnesota Region | Red Wing, MN | $6.56M |
| Mayo Clinic Health System-Fairmont | Fairmont, MN | $4.71M |
| Mayo Clinic Health System-Southeast Minnesota Region | Red Wing, MN | $4.42M |
| Mayo Clinic Health System-Southwest Minnesota Region | Waseca, MN | $2.72M |
| Mayo Clinic Health System-Southwest Minnesota Region | New Prague, MN | $1.41M |
| Mayo Clinic Health System-Lake City | Lake City, MN | $653K |
| Mayo Clinic Health System-Southeast Minnesota Region | Cannon Falls, MN | $520K |
| Mayo Clinic Health System-Lake City | Lake City, MN | $265K |
| Mayo Clinic Health System-Lake City | Lake City, MN | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.